

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 January 2002 (10.01.2002)


PCT

(10) International Publication Number
WO 02/02179 A1

- (51) International Patent Classification⁷: **A61M 37/00**
- (21) International Application Number: **PCT/US01/20782**
- (22) International Filing Date: **29 June 2001 (29.06.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
09/606,909 **29 June 2000 (29.06.2000)** **US**
- (71) Applicant (for all designated States except US): **BECTON, DICKINSON AND COMPANY [US/US]**; Intellectual Property Dept., Mail Code 089, 1 Becton Drive, Franklin Lakes, NJ 07417-1880 (US).
- (72) Inventors: and
- (75) Inventors/Applicants (for US only): **PETTIS, Ronald, J. [US/US]**; 529 Darby Glen Lane, Durham, NC 27713 (US). **DOWN, James, A. [US/US]**; 314 Oakely Court, Cary, NC 27511 (US). **HARVEY, Noel, G. [US/US]**; 3211 US 70 West, Efland, NC 27243 (US).
- (74) Agents: **SCHMIDT, Richard, D. et al.; Venable, Baetjer, Howard & Civiletti, LLP, Suite 1000, 1201 New York Avenue, NW, P.O. Box 34385, Washington, DC 20043-9998 (US).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: **MICRONEEDLE FOR DELIVERING A SUBSTANCE INTO THE DERMIS**



(57) Abstract: A method for directly delivering whereby a substance is introduced into an intradermal space within mammalian skin which involves administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm. The outlet is inserted into the skin to a depth of between .3 mm and 2 mm such that the delivery of the substance occurs at a depth between .3 mm and 2 mm.

WO 02/02179 A1



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

MICRONEEDLE FOR DELIVERING A SUBSTANCE INTO THE DERMIS

5 FIELD OF THE INVENTION

[0001] The present invention relates to methods and devices for administration of substances into the intradermal layer of skin.

CROSS REFERENCE TO RELATED APPLICATIONS

10 This application is a continuation-in-part of U.S. application No. 09/606,909 filed June 29, 2000.

BACKGROUND OF THE INVENTION

[0002] The importance of efficiently and safely administering pharmaceutical
15 substances such as diagnostic agents and drugs has long been recognized. Although an important consideration for all pharmaceutical substances, obtaining adequate bioavailability of large molecules such as proteins that have arisen out of the biotechnology industry has recently highlighted this need to obtain efficient and reproducible absorption (Cleland et al., *Curr. Opin. Biotechnol.* 12: 212-219, 2001). The
20 use of conventional needles has long provided one approach for delivering pharmaceutical substances to humans and animals by administration through the skin. Considerable effort has been made to achieve reproducible and efficacious delivery through the skin while improving the ease of injection and reducing patient apprehension and/or pain associated with conventional needles. Furthermore, certain delivery systems
25 eliminate needles entirely, and rely upon chemical mediators or external driving forces such as iontophoretic currents or electroporation or thermal poration or sonophoresis to breach the stratum corneum, the outermost layer of the skin, and deliver substances through the surface of the skin. However, such delivery systems do not reproducibly breach the skin barriers or deliver the pharmaceutical substance to a given depth below
30 the surface of the skin and consequently, clinical results can be variable. Thus, mechanical breach of the stratum corneum such as with needles, is believed to provide the most reproducible method of administration of substances through the surface of the skin, and to provide control and reliability in placement of administered substances.

5

[0003] Approaches for delivering substances beneath the surface of the skin have almost exclusively involved transdermal administration, i.e. delivery of substances through the skin to a site beneath the skin. Transdermal delivery includes subcutaneous, intramuscular or intravenous routes of administration of which, intramuscular (IM) and subcutaneous (SC) injections have been the most commonly used.

10

[0004] Anatomically, the outer surface of the body is made up of two major tissue layers, an outer epidermis and an underlying dermis, which together constitute the skin (for review, see *Physiology, Biochemistry, and Molecular Biology of the Skin, Second Edition*, L.A. Goldsmith, Ed., Oxford University Press, New York, 1991). The epidermis is subdivided into five layers or strata of a total thickness of between 75 and 150 μm . Beneath the epidermis lies the dermis, which contains two layers, an outermost portion referred to as the papillary dermis and a deeper layer referred to as the reticular dermis. The papillary dermis contains vast microcirculatory blood and lymphatic plexuses. In contrast, the reticular dermis is relatively acellular and avascular and made up of dense collagenous and elastic connective tissue. Beneath the epidermis and dermis is the subcutaneous tissue, also referred to as the hypodermis, which is composed of connective tissue and fatty tissue. Muscle tissue lies beneath the subcutaneous tissue.

15

20

[0005] As noted above, both the subcutaneous tissue and muscle tissue have been commonly used as sites for administration of pharmaceutical substances. The dermis, however, has rarely been targeted as a site for administration of substances, and this may be due, at least in part, to the difficulty of precise needle placement into the intradermal space. Furthermore, even though the dermis, in particular, the papillary dermis has been known to have a high degree of vascularity, it has not heretofore been appreciated that one could take advantage of this high degree of vascularity to obtain an improved absorption profile for administered substances compared to subcutaneous administration. This is because small drug molecules are typically rapidly absorbed after administration into the subcutaneous tissue which has been far more easily and predictably targeted than the dermis has been. On the other hand, large molecules such as proteins are typically not well absorbed through the capillary epithelium regardless of the degree of vascularity so that one would not have expected to achieve a significant absorption

30

35

5 advantage over subcutaneous administration by the more difficult to achieve intradermal administration even for large molecules.

10 [0006] One approach to administration beneath the surface to the skin and into the region of the intradermal space has been routinely used in the Mantoux tuberculin test. In this procedure, a purified protein derivative is injected at a shallow angle to the skin surface using a 27 or 30 gauge needle (Flynn et al, *Chest* 106: 1463-5, 1994). A degree of uncertainty in placement of the injection can, however, result in some false negative test results. Moreover, the test has involved a localized injection to elicit a response at the site of injection and the Mantoux approach has not led to the use of intradermal injection for systemic administration of substances.

20 [0007] Some groups have reported on systemic administration by what has been characterized as "intradermal" injection. In one such report, a comparison study of subcutaneous and what was described as "intradermal" injection was performed (Autret et al, *Therapie* 46:5-8, 1991). The pharmaceutical substance tested was calcitonin, a protein of a molecular weight of about 3600. Although it was stated that the drug was injected intradermally, the injections used a 4 mm needle pushed up to the base at an angle of 60. This would have resulted in placement of the injectate at a depth of about 3.5 mm and into the lower portion of the reticular dermis or into the subcutaneous tissue rather than into the vascularized papillary dermis. If, in fact, this group injected into the lower portion of the reticular dermis rather than into the subcutaneous tissue, it would be expected that the substance would either be slowly absorbed in the relatively less vascular reticular dermis or diffuse into the subcutaneous region to result in what would be functionally the same as subcutaneous administration and absorption. Such actual or functional subcutaneous administration would explain the reported lack of difference between subcutaneous and what was characterized as intradermal administration, in the times at which maximum plasma concentration was reached, the concentrations at each assay time and the areas under the curves.

35 [0008] Similarly, Bressolle et al. administered sodium ceftazidime in what was characterized as "intradermal" injection using a 4 mm needle (Bressolle et al. *J. Pharm. Sci.* 82:1175-1178, 1993). This would have resulted in injection to a depth of 4 mm

5 below the skin surface to produce actual or functional subcutaneous injection, although good subcutaneous absorption would have been anticipated in this instance because sodium ceftazidime is hydrophilic and of relatively low molecular weight.

[0009] Another group reported on what was described as an intradermal drug
10 delivery device (U.S. Patent No. 5,007,501). Injection was indicated to be at a slow rate and the injection site was intended to be in some region below the epidermis, i.e., the interface between the epidermis and the dermis or the interior of the dermis or subcutaneous tissue. This reference, however, provided no teachings that would suggest a selective administration into the dermis nor did the reference suggest any possible
15 pharmacokinetic advantage that might result from such selective administration.

[0010] Thus there remains a continuing need for efficient and safe methods and devices for administration of pharmaceutical substances.

20 SUMMARY OF THE INVENTION

[0011] The present disclosure relates to a new parenteral administration method based on directly targeting the dermal space whereby such method dramatically alters the pharmacokinetics (PK) and pharmacodynamics (PD) parameters of administered substances. By the use of direct intradermal (ID) administration means hereafter
25 referred to as dermal-access means, for example, using microneedle-based injection and infusion systems (or other means to accurately target the intradermal space), the pharmacokinetics of many substances including drugs and diagnostic substances, which are especially protein and peptide hormones, can be altered when compared to traditional parental administration routes of subcutaneous and intravenous delivery. These findings
30 are pertinent not only to microdevice-based injection means, but other delivery methods such as needless or needle-free ballistic injection of fluids or powders into the ID space, Mantoux-type ID injection, enhanced iontophoresis through microdevices, and direct deposition of fluid, solids, or other dosing forms into the skin. Disclosed is a method to increase the rate of uptake for parenterally-administered drugs without necessitating IV
35 access. One significant beneficial effect of this delivery method is providing a shorter T_{max} (time to achieve maximum blood concentration of the drug). Potential corollary benefits include higher maximum concentrations for a given unit dose (C_{max}), higher

5 bioavailability, more rapid uptake rates, more rapid onset of pharmacodynamics or biological effects, and reduced drug depot effects. According to the present invention, improved pharmacokinetics means increased bioavailability, decreased lag time (T_{lag}), decreased T_{max} , more rapid absorption rates, more rapid onset and/or increased C_{max} for a given amount of compound administered, compared to subcutaneous, intramuscular or
10 other non-IV parenteral means of drug delivery.

[0012] By bioavailability is meant the total amount of a given dosage that reached the blood compartment. This is generally measured as the area under the curve in a plot of concentration vs. time. By "lag time" is meant the delay between the administration
15 of a compound and time to measurable or detectable blood or plasma levels. T_{max} is a value representing the time to achieve maximal blood concentration of the compound, and C_{max} is the maximum blood concentration reached with a given dose and administration method. The time for onset is a function of T_{lag} , T_{max} and C_{max} , as all of these parameters influence the time necessary to achieve a blood (or target tissue)
20 concentration necessary to realize a biological effect. T_{max} and C_{max} can be determined by visual inspection of graphical results and can often provide sufficient information to compare two methods of administration of a compound. However, numerical values can be determined more precisely by analysis using kinetic models (as described below) and/or other means known to those of skill in the art.

25 [0013] Directly targeting the dermal space as taught by the invention provides more rapid onset of effects of drugs and diagnostic substances. The inventors have found that substances can be rapidly absorbed and systemically distributed via controlled ID administration that selectively accesses the dermal vascular and lymphatic
30 microcapillaries, thus the substances may exert their beneficial effects more rapidly than SC administration. This has special significance for drugs requiring rapid onset, such as insulin to decrease blood glucose, pain relief such as for breakthrough cancer pain, or migraine relief, or emergency rescue drugs such as adrenaline or anti-venom. Natural hormones are also released in pulsatile fashion with a rapid onset burst followed by rapid
35 clearance. Examples include insulin that is released in response to biological stimulus, for example high glucose levels. Another example is female reproductive hormones, which are released at time intervals in pulsatile fashion. Human growth hormone is also

5 released in normal patients in a pulsatile fashion during sleep. This benefit allows better therapy by mimicking the natural body rhythms with synthetic drug compounds. Likewise, it may better facilitate some current therapies such as blood glucose control via insulin delivery. Many current attempts at preparing "closed loop" insulin pumps are hindered by the delay period between administering the insulin and waiting for the
10 biological effect to occur. This makes it difficult to ascertain in real-time whether sufficient insulin has been given, without overtitrating and risking hypoglycemia. The more rapid PK/PD of ID delivery eliminates much of this type of problem.

[0014] Mammalian skin contains two layers, as discussed above, specifically, the
15 epidermis and dermis. The epidermis is made up of five layers, the stratum corneum, the stratum lucidum, the stratum granulosum, the stratum spinosum and the stratum germinativum and the dermis is made up of two layers, the upper papillary dermis and the deeper reticular dermis. The thickness of the dermis and epidermis varies from individual to individual, and within an individual, at different locations on the body. For
20 example, it has been reported that the epidermis varies in thickness from about 40 to about 90 μm and the dermis varies in thickness ranging from just below the epidermis to a depth of from less than 1 mm in some regions of the body to just under 2 to about 4 mm in other regions of the body depending upon the particular study report (Hwang et al., *Ann Plastic Surg* 46:327-331, 2001; Southwood, *Plast. Reconstr. Surg* 15:423-429, 1955; Rushmer et al., *Science* 154:343-348, 1966).
25

[0015] As used herein, intradermal is intended to mean administration of a substance into the dermis in such a manner that the substance readily reaches the richly vascularized papillary dermis and is rapidly absorbed into the blood capillaries and/or
30 lymphatic vessels to become systemically bioavailable. Such can result from placement of the substance in the upper region of the dermis, i.e. the papillary dermis or in the upper portion of the relatively less vascular reticular dermis such that the substance readily diffuses into the papillary dermis. It is believed that placement of a substance predominately at a depth of at least about 0.3 mm, more preferably, at least about 0.4
35 mm and most preferably at least about 0.5 mm up to a depth of no more than about 2.5 mm, more preferably, no more than about 2.0 mm and most preferably no more than about 1.7 mm will result in rapid absorption of macromolecular and/or hydrophobic

5 substances. Placement of the substance predominately at greater depths and/or into the lower portion of the reticular dermis is believed to result in the substance being slowly absorbed in the less vascular reticular dermis or in the subcutaneous region either of which would result in reduced absorption of macromolecular and/or hydrophobic substances. The controlled delivery of a substance in this dermal space below the
10 papillary dermis in the reticular dermis, but sufficiently above the interface between the dermis and the subcutaneous tissue, should enable an efficient (outward) migration of the substance to the (undisturbed) vascular and lymphatic microcapillary bed (in the papillary dermis), where it can be absorbed into systemic circulation via these microcapillaries without being sequestered in transit by any other cutaneous tissue
15 compartment.

[0016] Another benefit of the invention is to achieve more rapid systemic distribution and offset of drugs or diagnostic agents. This is also pertinent for many hormones that in the body are secreted in a pulsatile fashion. Many side effects are
20 associated with having continuous circulating levels of substances administered. A very pertinent example is female reproductive hormones that actually have the opposite effect (cause infertility) when continuously present in the blood. Likewise, continuous and elevated levels of insulin are suspected to down regulate insulin receptors both in quantity and sensitivity.

25 [0017] Another benefit of the invention is to achieve higher bioavailabilities of drugs or diagnostic agents. This effect has been most dramatic for ID administration of high molecular weight substances, especially proteins, peptides, and polysaccharides. The direct benefit is that ID administration with enhanced bioavailability, allows equivalent
30 biological effects while using less active agent. This results in direct economic benefit to the drug manufacturer and perhaps consumer, especially for expensive protein therapeutics and diagnostics. Likewise, higher bioavailability may allow reduced overall dosing and decrease the patient's side effects associated with higher dosing.

35 [0018] Another benefit of the invention is the attainment of higher maximum concentrations of drugs or diagnostic substances. The inventors have found that substances administered ID are absorbed more rapidly, with bolus administration

5 resulting in higher initial concentrations. This is most beneficial for substances whose efficacy is related to maximal concentration. The more rapid onset allows higher C_{Max} values to be reached with lesser amounts of the substance. Therefore, the dose can be reduced, providing an economic benefit, as well as a physiological benefit since lesser amounts of the drug or diagnostic agent has to be cleared by the body.

10

[0019] Another benefit of the invention is no change in systemic elimination rates or intrinsic clearance mechanisms of drugs or diagnostic agents. All studies to date by the applicants have maintained the same systemic elimination rate for the substances tested as via IV or SC dosing routes. This indicates this dosing route has no change in the biological mechanism for systemic clearance. This is an advantageous from a regulatory standpoint, since degradation and clearance pathways need not be reinvestigated prior to filing for FDA approval. This is also beneficial from a pharmacokinetics standpoint, since it allows predictability of dosing regimes. Some substances may be eliminated from the body more rapidly if their clearance mechanism are concentration dependent. Since ID delivery results in higher C_{max} , clearance rate may be increased, although the intrinsic mechanism remains unchanged.

20

[0020] Another benefit of the invention is no change in pharmacodynamic mechanism or biological response mechanism. As stated above, administered drugs by the methods taught by the applicants still exert their effects by the same biological pathways that are intrinsic to other delivery means. Any pharmacodynamic changes are related only to the difference patterns of appearance, disappearance, and drug or diagnostic agent concentrations present in the biological system.

25

[0021] Using the methods of the present invention, pharmaceutical compounds may be administered as a bolus, or by infusion. As used herein, the term "bolus" is intended to mean an amount that is delivered within a time period of less than ten (10) minutes. "Infusion" is intended to mean the delivery of a substance over a time period greater than ten (10) minutes. It is understood that bolus administration or delivery can be carried out with rate controlling means, for example a pump, or have no specific rate controlling means, for example user self-injection.

30

35

5 [0022] Another benefit of the invention is removal of the physical or kinetic barriers invoked when drugs passes through and becomes trapped in cutaneous tissue compartments prior to systemic absorption. Elimination of such barriers leads to an extremely broad applicability to various drug classes. Many drugs administered subcutaneously exert this depot effect -- that is, the drug is slowly released from the SC
10 space, in which it is trapped, as the rate determining step prior to systemic absorption, due to affinity for or slow diffusion through the fatty adipose tissue. This depot effect results in a lower C_{max} and longer T_{max} , compared to ID, and can result in high inter-individual variability of absorption. This effect is also pertinent for comparison to transdermal delivery methods including passive patch technology, with or without
15 permeation enhances, iontophoretic technology, sonophoresis, or stratum corneum ablation or disruptive methods. Transdermal patch technology relies on drug partitioning through the highly impermeable stratum corneum and epidermal barriers. Few drugs except highly lipophilic compounds can breach this barrier, and those that do, often exhibit extended offset kinetics due to tissue saturation and entrapment of the
20 drugs. Active transdermal means, while often faster than passive transfer means, are still restricted to compound classes that can be moved by charge repulsion or other electronic or electrostatic means, or carried passively through the transient pores caused by cavitation of the tissue during application of sound waves. The stratum corneum and epidermis still provide effective means for inhibiting this transport. Stratum corneum
25 removal by thermal or laser ablation, abrasive means or otherwise, still lacks a driving force to facilitate penetration or uptake of drugs. Direct ID administration by mechanical means overcomes the kinetic barrier properties of skin, and is not limited by the pharmaceutical or physicochemical properties of the drug or its formulation excipients.

30

[0023] Another benefit of the invention is highly controllable dosing regimens. The applicants have determined that ID infusion studies have demonstrated dosing profiles that are highly controllable and predictable due to the rapid onset and offset kinetics of drugs or diagnostic agents delivered by this route. This allows almost absolute control
35 over the desired dosing regimen when ID delivery is coupled with a fluid control means or other control system to regulate metering of the drug or diagnostic agent into the body. This single benefit alone is one of the principal goals of most drug or diagnostic

5 agent delivery methods. Bolus ID substance administration as defined previously results in kinetics most similar to IV injection and is most desirable for pain relieving compounds, mealtime insulin, rescue drugs, erectile dysfunction compounds, or other drugs that require rapid onset. Also included would be combinations of substances capable of acting alone or synergistically. Extending the ID administration duration via
10 infusion can effectively mimic SC uptake parameters, but with better predictability. This profile is particularly good for substances such as growth hormones, or analgesics. Longer duration infusion, typically at lower infusion rates can result in continuous low basal levels of drugs that is desired for anticoagulants, basal insulin, and chronic pain therapy. These kinetic profiles can be combined in multiple fashion to exhibit almost
15 any kinetic profile desired. An example would be to pulsatile delivery of fertility hormone (LHRH) for pregnancy induction, which requires intermittent peaks every 90 minutes with total clearance between pulses. Other examples would be rapid peak onset of drugs for migraine relief, followed by lower levels for pain prophylaxis.

20 [0024] Another benefit of the invention is reduced degradation of drugs and diagnostic agents and/or undesirable immunogenic activity. Transdermal methods using chemical enhancers or iontophoresis, or sonophoresis or electroporation or thermal poration require that a drug pass through the viable epidermal layer, which has high metabolic and immunogenic activity. Metabolic conversion of substances in the
25 epidermis or sequestration by immunoglobulins reduces the amount of drug available for absorption. The ID administration circumvents this problem by placing the drug directly in the dermis, thus bypassing the epidermis entirely.

[0025] These and other benefits of the invention are achieved by directly targeting
30 absorption by the papillary dermis and by controlled delivery of drugs, diagnostic agents, and other substances to the dermal space of skin. The inventors have found that by specifically targeting the intradermal space and controlling the rate and pattern of delivery, the pharmacokinetics exhibited by specific drugs can be unexpectedly improved, and can in many situations be varied with resulting clinical advantage. Such
35 pharmacokinetics cannot be as readily obtained or controlled by other parenteral administration routes, except by IV access.

5 [0026] The present invention improves the clinical utility of ID delivery of drugs, diagnostic agents, and other substances to humans or animals. The methods employ dermal-access means (for example a small gauge needle, especially microneedles), to directly target the intradermal space and to deliver substances to the intradermal space as a bolus or by infusion. It has been discovered that the placement of the dermal-access
10 means within the dermis provides for efficacious delivery and pharmacokinetic control of active substances. The dermal-access means is so designed as to prevent leakage of the substance from the skin and improve adsorption within the intradermal space. The pharmacokinetics of hormone drugs delivered according to the methods of the invention have been found to be vastly different to the pharmacokinetics of conventional SC
15 delivery of the drug, indicating that ID administration according to the methods of the invention will provide improved clinical results. Delivery devices that place the dermal-access means at an appropriate depth in the intradermal space and control the volume and rate of fluid delivery provide accurate delivery of the substance to the desired location without leakage.

20 [0027] Disclosed is a method to increase the rate of uptake for parenterally-administered drugs without necessitating IV access. This effect provides a shorter T_{max} . Potential corollary benefits include higher maximum concentrations for a given unit dose (C_{max}), higher bioavailability, more rapid onset of pharmacodynamics or biological
25 effects, and reduced drug depot effects.

 [0028] It has also been found that by appropriate depth control of the dermal-access means within the intradermal space that the pharmacokinetics of hormone drugs delivered according to the methods of the invention can, if required, produce similar
30 clinical results to that of conventional SC delivery of the drug.

 [0029] The pharmacokinetic profile for individual compounds will vary according to the chemical properties of the compounds. For example, compounds that are relatively large, having a molecular weight of at least 1000 Daltons as well as larger compounds of
35 at least 2000 Daltons, at least 4000 Daltons, at least 10,000 Daltons and larger and/or hydrophobic compounds are expected to show the most significant changes compared to traditional parenteral methods of administration, such as intramuscular, subcutaneous or

5 subdermal injection. It is expected that small hydrophilic substances, on the whole, will exhibit similar kinetics for ID delivery compared to other methods.

DESCRIPTION OF THE DRAWINGS

10 [0030] Figure 1 shows a time course of plasma insulin levels of intradermal versus subcutaneous bolus administration of fast-acting.

[0031] Figure 2 shows a time course of blood glucose levels of intradermal versus subcutaneous bolus administration of fast-acting insulin.

[0032] Figure 3 shows a comparison of bolus ID dosing of fast-acting versus regular insulin.

15 [0033] Figure 4 shows the effects of different intradermal injection depths for bolus dosing of fast-acting insulin on the time course of insulin levels

[0034] Figure 5 shows a comparison of the time course of insulin levels for bolus dosing of long-acting insulin administered subcutaneously or intradermally.

20 [0035] Figure 6 and 7 show a comparison of the pharmacokinetic availability and the pharmacodynamic results of granulocyte colony stimulating factor delivered intradermally with a single needle or three point needle array, subcutaneously, or intravenously.

[0036] Figures 8, 9 and 10 show a comparison of low molecular weight heparin intradermal delivery by bolus, short duration, long duration infusion with comparison to
25 subcutaneous infusion.

DETAILED DESCRIPTION OF THE INVENTION

[0037] The present invention provides a method for therapeutic treatment by delivery of a drug or other substance to a human or animal subject by directly targeting
30 the intradermal space, where the drug or substance is administered to the intradermal space through one or more dermal-access means incorporated within the device. Substances infused according to the methods of the invention have been found to exhibit pharmacokinetics superior to, and more clinically desirable than that observed for the same substance administered by SC injection.

35

[0038] The dermal-access means used for ID administration according to the invention is not critical as long as it penetrates the skin of a subject to the desired

5 targeted depth within the intradermal space without passing through it. In most cases, the device will penetrate the skin and to a depth of about 0.5-2 mm. The dermal-access means may comprise conventional injection needles, catheters or microneedles of all known types, employed singularly or in multiple needle arrays. The dermal-access means may comprise needleless devices including ballistic injection devices. The terms
10 "needle" and "needles" as used herein are intended to encompass all such needle-like structures. The term microneedles as used herein are intended to encompass structures smaller than about 30 gauge, typically about 31-50 gauge when such structures are cylindrical in nature. Non-cylindrical structures encompass by the term microneedles would therefore be of comparable diameter and include pyramidal, rectangular,
15 octagonal, wedged, and other geometrical shapes. Dermal-access means also include ballistic fluid injection devices, powder-jet delivery devices, piezoelectric, electromotive, electromagnetic assisted delivery devices, gas-assisted delivery devices, of which directly penetrate the skin to provide access for delivery or directly deliver substances to the targeted location within the dermal space. By varying the targeted
20 depth of delivery of substances by the dermal-access means, pharmacokinetic and pharmacodynamic (PK/PD) behavior of the drug or substance can be tailored to the desired clinical application most appropriate for a particular patient's condition. The targeted depth of delivery of substances by the dermal-access means may be controlled manually by the practitioner, or with or without the assistance of indicator means to
25 indicate when the desired depth is reached. Preferably however, the device has structural means for controlling skin penetration to the desired depth within the intradermal space. This is most typically accomplished by means of a widened area or hub associated with the shaft of the dermal-access means that may take the form of a backing structure or platform to which the needles are attached. The length of
30 microneedles as dermal-access means are easily varied during the fabrication process and are routinely produced in less than 2 mm length. Microneedles are also a very sharp and of a very small gauge, to further reduce pain and other sensation during the injection or infusion. They may be used in the invention as individual single-lumen microneedles or multiple microneedles may be assembled or fabricated in linear arrays or two-
35 dimensional arrays as to increase the rate of delivery or the amount of substance delivered in a given period of time. Microneedles may be incorporated into a variety of devices such as holders and housings that may also serve to limit the depth of

5 penetration. The dermal-access means of the invention may also incorporate reservoirs to contain the substance prior to delivery or pumps or other means for delivering the drug or other substance under pressure. Alternatively, the device housing the dermal-access means may be linked externally to such additional components.

10 [0039] IV-like pharmacokinetics is accomplished by administering drugs into the dermal compartment in intimate contact with the capillary microvasculature and lymphatic microvasculature. It should be understood that the terms microcapillaries or capillary beds refer to either vascular or lymphatic drainage pathways within the dermal area.

15 [0040] While not intending to be bound by any theoretical mechanism of action, it is believed that the rapid absorption observed upon administration into the dermis is achieved as a result of the rich plexuses of blood and lymphatic vessels in the dermis. However, the presence of blood and lymphatic plexuses in the dermis would not by itself
20 be expected to produce an enhanced absorption of macromolecules. This is because capillary endothelium is normally of low permeability or impermeable to macromolecules such as proteins, polysaccharides, nucleic acid polymers, substance having polymers attached such as pegylated proteins and the like. Such macromolecules have a molecular weight of at least 1000 Daltons or of a higher molecular weight of at
25 least, 2000 Daltons, at least 4000 Daltons, at least 10,000 Daltons or even higher. Furthermore, a relatively slow lymphatic drainage from the interstitium into the vascular compartment would also not be expected to produce a rapid increase in plasma concentration upon placement of a pharmaceutical substance into the dermis.

30 [0041] One possible explanation for the unexpected enhanced absorption reported herein is that upon injection of substances so that they readily reach the papillary dermis an increase in blood flow and capillary permeability results. For example, it is known that a pinprick insertion to a depth of 3 mm produces an increase in blood flow and this has been postulated to be independent of pain stimulus and due to tissue release of
35 histamine (Arildsson et al., *Microvascular Res.* 59:122-130, 2000). This is consistent with the observation that an acute inflammatory response elicited in response to skin injury produces a transient increase in blood flow and capillary permeability (see

5 *Physiology, Biochemistry, and Molecular Biology of the Skin, Second Edition*, L.A. Goldsmith, Ed., Oxford Univ. Press, New York, 1991, p. 1060; Wilhem, *Rev. Can. Biol.* 30:153-172, 1971). At the same time, the injection into the intradermal layer would be expected to increase interstitial pressure. It is known that increasing interstitial pressure from values (beyond the "normal range") of about -7 to about +2 mmHg distends
10 lymphatic vessels and increases lymph flow (Skobe et al., *J. Investig. Dermatol. Symp. Proc.* 5:14-19, 2000). Thus, the increased interstitial pressure elicited by injection into the intradermal layer is believed to elicit increased lymph flow and increased absorption of substances injected into the dermis.

15 [0042] By "improved pharmacokinetics" it is meant that an enhancement of pharmacokinetic profile is achieved as measured, for example, by standard pharmacokinetic parameters such as time to maximal plasma concentration (T_{max}), the magnitude of maximal plasma concentration (C_{max}) or the time to elicit a minimally detectable blood or plasma concentration (T_{lag}). By enhanced absorption profile, it is
20 meant that absorption is improved or greater as measured by such pharmacokinetic parameters. The measurement of pharmacokinetic parameters and determination of minimally effective concentrations are routinely performed in the art. Values obtained are deemed to be enhanced by comparison with a standard route of administration such as, for example, subcutaneous administration or intramuscular administration. In such
25 comparisons, it is preferable, although not necessarily essential, that administration into the intradermal layer and administration into the reference site such as subcutaneous administration involve the same dose levels, i.e. the same amount and concentration of drug as well as the same carrier vehicle and the same rate of administration in terms of amount and volume per unit time. Thus, for example, administration of a given
30 pharmaceutical substance into the dermis at a concentration such as 100 µg/ml and rate of 100 µL per minute over a period of 5 minutes would, preferably, be compared to administration of the same pharmaceutical substance into the subcutaneous space at the same concentration of 100 µg/ml and rate of 100 µL per minute over a period of 5 minutes.

35 [0043] The enhanced absorption profile is believed to be particularly evident for substances which are not well absorbed when injected subcutaneously such as, for

5 example, macromolecules and/or hydrophobic substances. Macromolecules are, in
general, not well absorbed subcutaneously and this may be due, not only to their size
relative to the capillary pore size, it may also be due to their slow diffusion through the
interstitium because of their size. It is understood that macromolecules can possess
discrete domains having a hydrophobic and/or hydrophilic nature. In contrast, small
10 molecules which are hydrophilic are generally well absorbed when administered
subcutaneously and it is possible that no enhanced absorption profile would be seen
upon injection into the dermis compared to absorption following subcutaneous
administration. Reference to hydrophobic substances herein is intended to mean low
molecular weight substances, for example substances with molecular weights less than
15 1000 Daltons, which have a water solubility which is low to substantially insoluble

[0044] The above-mentioned PK and PD benefits are best realized by accurate direct
targeting of the dermal capillary beds. This is accomplished, for example, by using
microneedle systems of less than about 250 micron outer diameter, and less than 2 mm
20 exposed length. Such systems can be constructed using known methods of various
materials including steel, silicon, ceramic, and other metals, plastic, polymers, sugars,
biological and or biodegradable materials, and/or combinations thereof.

[0045] It has been found that certain features of the intradermal administration
25 methods provide clinically useful PK/PD and dose accuracy. For example, it has been
found that placement of the needle outlet within the skin significantly affects PK/PD
parameters. The outlet of a conventional or standard gauge needle with a bevel has a
relatively large exposed height (the vertical rise of the outlet). Although the needle tip
may be placed at the desired depth within the intradermal space, the large exposed height
30 of the needle outlet causes the delivered substance to be deposited at a much shallower
depth nearer to the skin surface. As a result, the substance tends to effuse out of the skin
due to backpressure exerted by the skin itself and to pressure built up from accumulating
fluid from the injection or infusion. That is, at a greater depth a needle outlet with a
greater exposed height will still seal efficiently where as an outlet with the same exposed
35 height will not seal efficiently when placed in a shallower depth within the intradermal
space. Typically, the exposed height of the needle outlet will be from 0 to about 1 mm.
A needle outlet with an exposed height of 0 mm has no bevel and is at the tip of the

5 needle. In this case, the depth of the outlet is the same as the depth of penetration of the needle. A needle outlet that is either formed by a bevel or by an opening through the side of the needle has a measurable exposed height. It is understood that a single needle may have more than one opening or outlets suitable for delivery of substances to the dermal space.

10

[0046] It has also been found that by controlling the pressure of injection or infusion may avoid the high backpressure exerted during ID administration. By placing a constant pressure directly on the liquid interface a more constant delivery rate can be achieved, which may optimize absorption and obtain the improved pharmacokinetics.

15 Delivery rate and volume can also be controlled to prevent the formation of wheals at the site of delivery and to prevent backpressure from pushing the dermal-access means out of the skin. The appropriate delivery rates and volumes to obtain these effects for a selected substance may be determined experimentally using only ordinary skill.

Increased spacing between multiple needles allows broader fluid distribution and

20 increased rates of delivery or larger fluid volumes. In addition, it has been found that ID infusion or injection often produces higher initial plasma levels of drug than conventional SC administration, particularly for drugs that are susceptible to in vivo degradation or clearance or for compounds that have an affinity to the SC adipose tissue or for macromolecules that diffuse slowly through the SC matrix. This may, in many

25 cases, allow for smaller doses of the substance to be administered via the ID route.

[0047] The administration methods useful for carrying out the invention include both bolus and infusion delivery of drugs and other substances to humans or animals subjects. A bolus dose is a single dose delivered in a single volume unit over a relatively brief

30 period of time, typically less than about 10 minutes. Infusion administration comprises administering a fluid at a selected rate that may be constant or variable, over a relatively more extended time period, typically greater than about 10 minutes. To deliver a substance the dermal-access means is placed adjacent to the skin of a subject providing directly targeted access within the intradermal space and the substance or substances are

35 delivered or administered into the intradermal space where they can act locally or be absorbed by the bloodstream and be distributed systematically. The dermal-access means may be connected to a reservoir containing the substance or substances to be

5 delivered. The form of the substance or substances to be delivered or administered
include solutions thereof in pharmaceutically acceptable diluents or solvents, emulsions,
suspensions, gels, particulates such as micro- and nanoparticles either suspended or
dispersed, as well as in-situ forming vehicles of the same. Delivery from the reservoir
into the intradermal space may occur either passively, without application of the external
10 pressure or other driving means to the substance or substances to be delivered, and/or
actively, with the application of pressure or other driving means. Examples of preferred
pressure generating means include pumps, syringes, elastomer membranes, gas pressure,
piezoelectric, electromotive, electromagnetic pumping, or Belleville springs or washers
or combinations thereof. If desired, the rate of delivery of the substance may be variably
15 controlled by the pressure-generating means. As a result, the substance enters the
intradermal space and is absorbed in an amount and at a rate sufficient to produce a
clinically efficacious result.

[0048] As used herein, the term "clinically efficacious result" is meant a clinically
20 useful biological response including both diagnostically and therapeutically useful
responses, resulting from administration of a substance or substances. For example,
diagnostic testing or prevention or treatment of a disease or condition is a clinically
efficacious result. Such clinically efficacious results include diagnostic results such as
the measurement of glomerular filtration pressure following injection of inulin, the
25 diagnosis of adrenocortical function in children following injection of ACTH, the
causing of the gallbladder to contract and evacuate bile upon injection of
cholecystokinin and the like as well as therapeutic results, such as clinically adequate
control of blood sugar levels upon injection of insulin, clinically adequate management
of hormone deficiency following hormone injection such as parathyroid hormone or
30 growth hormone, clinically adequate treatment of toxicity upon injection of an antitoxin
and the like.

[0049] Substances that can be delivered intradermally in accordance with the present
invention are intended to include pharmaceutically or biologically active substances
35 including include diagnostic agents, drugs, and other substances which provide
therapeutic or health benefits such as for example nutraceuticals. Diagnostic substances
useful with the present invention include macromolecular substances such as, for

5 example, inulin, ACTH (e.g. corticotropin injection), luteinizing hormone-releasing hormone (eg., Gonadorelin Hydrochloride), growth hormone-releasing hormone (e.g. Sermorelin Acetate), cholecystokinin (Sincalide), parathyroid hormone and fragments thereof (e.g. Teriparatide Acetate), thyroid releasing hormone and analogs thereof (e.g. protirelin), secretin and the like.

10

[0050] Therapeutic substances which can be used with the present invention include Alpha-1 anti-trypsin, Anti-Angiogenesis agents, Antisense, butorphanol, Calcitonin and analogs, Ceredase, COX-II inhibitors, dermatological agents, dihydroergotamine, Dopamine agonists and antagonists, Enkephalins and other opioid peptides, Epidermal
15 growth factors, Erythropoietin and analogs, Follicle stimulating hormone, G-CSF, Glucagon, GM-CSF, granisetron, Growth hormone and analogs (including growth hormone releasing hormone), Growth hormone antagonists, Hirudin and Hirudin analogs such as Hirulog, IgE suppressors, Insulin, insulinotropin and analogs, Insulin-like growth factors, Interferons, Interleukins, Luteinizing hormone, Luteinizing hormone
20 releasing hormone and analogs, Heparins, Low molecular weight heparins and other natural, modified, or syntheic glycoaminoglycans, M-CSF, metoclopramide, Midazolam, Monoclonal antibodies, Peglyated antibodies, Pegylated proteins or any proteins modified with hydrophilic or hydrophobic polymers or additional functional groups, Fusion proteins, Single chain antibody fragments or the same with any combination of
25 attached proteins, macromolecules, or additional functional groups thereof, Narcotic analgesics, nicotine, Non-steroid anti-inflammatory agents, Oligosaccharides, ondansetron, Parathyroid hormone and analogs, Parathyroid hormone antagonists, Prostaglandin antagonists, Prostaglandins, Recombinant soluble receptors, scopolamine, Serotonin agonists and antagonists, Sildenafil, Terbutaline, Thrombolytics, Tissue
30 plasminogen activators, TNF - , and TNF - antagonist, the vaccines, with or without carriers/adjuvants, including prophylactics and therapeutic antigens (including but not limited to subunit protein, peptide and polysaccharide, polysaccharide conjugates, toxoids, genetic based vaccines, live attenuated, reassortant, inactivated, whole cells, viral and bacterial vectors) in connection with, addiction, arthritis, cholera, cocaine
35 addiction, diphtheria, tetanus, HIB, Lyme disease, meningococcus, measles, mumps, rubella, varicella, yellow fever, Respiratory syncytial virus, tick borne japanese encephalitis, pneumococcus, streptococcus, typhoid, influenza, hepatitis, including

5 hepatitis A, B, C and E, otitis media, rabies, polio, HIV, parainfluenza, rotavirus, Epstein
Barr Virus, CMV, chlamydia, non-typeable haemophilus, moraxella catarrhalis, human
papilloma virus, tuberculosis including BCG, gonorrhoea, asthma, atherosclerosis
malaria, E-coli, Alzheimer's Disease, H. Pylori, salmonella, diabetes, cancer, herpes
10 simplex, human papilloma and the like other substances including all of the major
therapeutics such as agents for the common cold, Anti-addiction, anti-allergy, anti-
emetics, anti-obesity, antiosteoporotic, anti-infectives, analgesics, anesthetics,
anorexics, antiarthritics, antiasthmatic agents, anticonvulsants, anti-depressants,
antidiabetic agents, antihistamines, anti-inflammatory agents, antimigraine preparations,
15 antinausea preparations, antinauseants, antineoplastics, antiparkinsonism drugs,
antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antagonists,
vasodilators, including general, coronary, peripheral and cerebral, bone stimulating
agents, central nervous system stimulants, hormones, hypnotics, immunosuppressives,
muscle relaxants, parasympatholytics, parasympathomimetics, prostaglandins, proteins,
20 peptides, polypeptides and other macromolecules, psychostimulants, sedatives, and
sexual hypofunction and tranquilizers.

[0051] Pharmacokinetic analysis of insulin infusion data was carried out as follows.
Stepwise nonlinear least-squares regression was used to analyze the insulin
concentration-time data from each individual animal. Initially, an empirical
25 biexponential equation was fit to the insulin concentration-time data for the negative
control condition. This analysis assumed first-order release of residual insulin, and
recovered parameters for the first-order rate constant for release, the residual insulin
concentration at the release site, a lag time for release, and a first-order rate constant for
elimination of insulin from the systemic circulation. The parameters recovered in this
30 phase of the analysis are of no intrinsic importance, but merely account for the fraction
of circulating insulin derived from endogenous sources.

[0052] The second step of the analysis involved fitting an explicit compartmental
model to the insulin concentration-time data during and after subcutaneous or
35 intradermal infusion. The scheme upon which the mathematical model was based is
shown in the upper part of Figure 1.[PK/PD model fig]. Infusion of insulin proceeded
from $t = 0$ to $t = 240$ min; after a lag time (t_{lag2}), absorption from the infusion site was

5 mediated by a first-order process governed by the absorption rate constant k_a . Insulin absorbed into the systemic circulation distributed into an apparent volume V contaminated by an unknown fractional bioavailability F , and was eliminated according to a first-order rate constant K . The fitting routine recovered estimates of $t_{lag,2}$, k_a , V/F , and K ; parameters associated with the disposition of endogenous insulin (C_R , $t_{lag,1}$, k_R),
 10 which were recovered in the first step of the analysis, were treated as constants.

[0053] Parameter estimates are reported as mean \pm SD. The significance of differences in specific parameters between the two different modes of insulin administration (subcutaneous versus intradermal infusion) was assessed with the paired
 15 Student's t-test.

Pharmacodynamic analysis of insulin infusion data was calculated as follows. Plasma concentrations of glucose were used as a surrogate for the pharmacological effect of insulin. The change in response variable R (plasma glucose concentration) with respect
 20 to time t was modeled as

$$\frac{dR}{dt} = k_{in} - E \cdot k_{out}$$

[0054] where k_{in} is the zero-order infusion of glucose, k_{out} is the first-order rate constant mediating glucose elimination, and E is the effect of insulin according to the sigmoid Hill relationship
 25

$$E = \frac{E_{max} \cdot C^\gamma}{EC_{50}^\gamma + C^\gamma}$$

[0055] in which M_{ax} is the maximal stimulation of k_{out} by insulin, EC_{50} is the insulin concentration at which stimulation of k_{out} is half maximal, C is the concentration of
 30 insulin, and γ is the Hill coefficient of the relationship. Initial modeling efforts utilized the plasma concentration of insulin as the mediator of pharmacological response. However, this approach did not capture the delay in response of plasma glucose to increasing concentrations of plasma insulin. Therefore, an effect-compartment modeling
 35 approach was finally adopted in which the effect of insulin was mediated from a

5 hypothetical effect compartment peripheral to the systemic pharmacokinetic compartment

10 [0056] The pharmacodynamic analysis was conducted in two steps. In the first step of the analysis, initial estimates of the pharmacokinetic parameters associated with the disposition of glucose (C_{0ut} and the volume of distribution of glucose, $V_{glucose}$) were determined from the glucose concentration-time data in the negative control condition. The full integrated pharmacokinetic-pharmacodynamic model then was fit simultaneously to the glucose concentration-time data from the negative control condition and each insulin delivery condition for each animal (i.e., two sets of

15 pharmacodynamic parameters were obtained for each animal: one from the simultaneous analysis of the subcutaneous insulin infusion/negative control data, and one from the simultaneous analysis of the intradermal insulin infusion/negative control data). In all pharmacodynamic analyses, the parameters governing insulin disposition obtained during pharmacokinetic analysis of insulin concentration-time data from each animal

20 were held constant.

[0057] All other pharmacokinetic analyses were calculated using non-compartmental methods using similar software programs and techniques known in the art.

25 [0058] Having described the invention in general, the following specific but not limiting examples and reference to the accompanying Figures set forth various examples for practicing the dermal accessing, direct targeting drug administration method and examples of dermal administered drug substances providing improved PK and PD effects.

30 [0059] A representative example of dermal-access microdevice comprising a single needle were prepared from 34 gauge steel stock (MicroGroup, Inc., Medway, MA) and a single 28° bevel was ground using an 800 grit carborundum grinding wheel. Needles were cleaned by sequential sonication in acetone and distilled water, and flow-checked with distilled water. Microneedles were secured into small gauge catheter tubing

35 (Maersk Medical) using UV-cured epoxy resin. Needle length was set using a mechanical indexing plate, with the hub of the catheter tubing acting as a depth-limiting

5 control and was confirmed by optical microscopy. For experiments using needles of various lengths, the exposed needle lengths were adjusted to 0.5, 0.8, 1, 2 or 3 mm using the indexing plate. Connection to the fluid metering device, either pump or syringe, was via an integral Luer adapter at the catheter inlet. During injection, needles were inserted perpendicular to the skin surface, and were either held in place by gentle hand pressure
10 for bolus delivery or held upright by medical adhesive tape for longer infusions. Devices were checked for function and fluid flow both immediately prior to and post injection. This Luer Lok single needle catheter design is hereafter designated SS1_34.

[0060] Yet another dermal-access array microdevices was prepared consisting of 1”
15 diameter disks machined from acrylic polymer, with a low volume fluid path branching to each individual needle from a central inlet. Fluid input was via a low volume catheter line connected to a Hamilton microsyringe, and delivery rate was controlled via a syringe pump. Needles were arranged in the disk with a circular pattern of 15 mm diameter. Three-needle and six-needle arrays were constructed, with 12 and 7 mm
20 needle-to-needle spacing, respectively. All array designs used single-bevel, 34 G stainless steel microneedles of 1 mm length. The 3-needle 12mm spacing catheter-design is hereafter designated SS3_34B, 6-needle 7mm spacing catheter-design is hereafter designated SS6_34A.

25 [0061] Yet another dermal-access array microdevices was prepared consisting of 11mm diameter disks machined from acrylic polymer, with a low volume fluid path branching to each individual needle from a central inlet. Fluid input was via a low volume catheter line connected to a Hamilton microsyringe, and delivery rate was controlled via a syringe pump. Needles were arranged in the disk with a circular pattern
30 of about 5 mm diameter. Three-needle arrays of about 4 mm spacing connected to a catheter as described above. These designs are hereafter designated SS3S_34_1, SS3C_34_2, and SS3S_34_3 for 1mm, 2mm, and 3mm needle lengths respectively.

[0062] Yet another dermal-access ID infusion device was constructed using a
35 stainless steel 30 gauge needle bent at near the tip at a 90-degree angle such that the available length for skin penetration was 1-2 mm. The needle outlet (the tip of the needle) was at a depth of 1.7-2.0 mm in the skin when the needle was inserted and the

5 total exposed height of the needle outlet 1.0-1.2 mm This design is hereafter designated SSB1_30.

[0063] EXAMPLE I

[0064] Slow-infusion ID insulin delivery was demonstrated in swine using a hollow,
10 silicon-based single-lumen microneedle (2 mm total length and 200 X 100 μ m OD, corresponding to about 33 gauge) with an outlet 1.0 μ m from the tip (100 μ m exposed height), was fabricated using processes known in the art (US Patent No. 5,928,207) and mated to a microbore catheter (Disetronic). The distal end of the microneedle was placed into the plastic catheter and cemented in place with epoxy resin to form a depth-
15 limiting hub. The needle outlet was positioned approximately 1 mm beyond the epoxy hub, thus limiting penetration of the needle outlet into the skin to approximately 1 mm., which corresponds to the depth of the intradermal space in swine.. The catheter was attached to a MiniMed 507 insulin pump for control of fluid delivery. The distal end of the microneedle was placed into the plastic catheter and cemented in place with epoxy
20 resin to form a depth-limiting hub. The needle outlet was positioned approximately 1 mm beyond the epoxy hub, thus limiting penetration of the needle outlet into the skin to approximately 1 mm., which corresponds to the depth of the intradermal space in swine. The patency of the fluid flow path was confirmed by visual observation, and no obstructions were observed at pressures generated by a standard 1-cc syringe. The
25 catheter was connected to an external insulin infusion pump (MiniMed 507) via the integral Luer connection at the catheter outlet. The pump was filled with HumalogTM (Lispro) insulin (Eli Lilly, Indianapolis, IN) and the catheter and microneedle were primed with insulin according to the manufacturer's instructions. Sandostatin® (Sandoz, East Hanover, NJ) solution was administered via IV infusion to anesthetized swine to
30 suppress basal pancreatic function and insulin secretion. After a suitable induction period and baseline sampling, the primed microneedle was inserted perpendicular to the skin surface in the flank of the animal up to the hub stop. Insulin infusion at a rate of 2 U/hr was used and maintained for 4 hr. Blood samples were periodically withdrawn and analyzed for serum insulin concentration and blood glucose values. Baseline insulin
35 levels before infusion were at the background detection level of the assay. After initiation of the infusion, serum insulin levels showed an increase that was

5 commensurate with the programmed infusion rates. Blood glucose levels also showed a
corresponding drop relative to negative controls (NC) without insulin infusion and this
drop was improved relative to conventional SC infusion. In this experiment, the
microneedle was demonstrated to adequately breach the skin barrier and deliver a drug
10 *in vivo* at pharmaceutically relevant rates. The ID infusion of insulin was demonstrated
to be a pharmacokinetically acceptable administration route, and the pharmacodynamic
response of blood glucose reduction was also demonstrated. Calculated PK parameters
for ID infusion indicate that insulin is absorbed much faster than via than SC
administration. Absorption from the ID space begins almost immediately: the lag time
prior to absorption (t_{lag}) was 0.88 vs. 13.6 min for ID and SC respectively. Also the rate
15 of uptake from the administration site is increased by approximately 3-fold, $k_a = 0.0666$
vs. 0.0225 min^{-1} for ID and SC respectively. The bioavailability of insulin delivered by
ID administration is increased approximately 1.3 fold greater than SC administration.

[0065] EXAMPLE II Bolus delivery of Lilly Lispro fast acting insulin was
20 performed using ID and SC bolus administration. The ID injection microdevice was
dermal access array design SS3_34. 10 international insulin units (U) corresponding to
100 uL volume respectively, were administered to diabetic Yucatan Mini swine. Test
animals had been previously been rendered diabetic by chemical ablation of pancreatic
islet cells, and were no longer able to secrete insulin. Test animals received their insulin
25 injection either via the microneedle array or via a standard 30 G X ½ in. needle inserted
laterally into the SC tissue space. Circulating serum insulin levels were detected using a
commercial chemiluminescent assay kit (Immulite, Los Angeles, CA) and blood
glucose values were determined using blood glucose strips. ID injections were
accomplished via hand pressure using an analytical microsyringe and were administered
30 over approximately 60 sec. By comparison, SC dosing required only 2-3 sec. Referring
to Figure 1, it is shown that serum insulin levels after bolus administration demonstrate
more rapid uptake and distribution of the injected insulin when administered via the ID
route. The time to maximum concentration (T_{max}) is shorter and the maximum
concentration obtained (C_{max}) is higher for ID vs. SC administration. In addition, Figure
35 2 also demonstrates the pharmacodynamic biological response to the administered
insulin, as measured by the decrease in blood glucose (BG), showed faster and greater
changes in BG since more insulin was available early after ID administration.

5

[0066] EXAMPLE III

[0067] Lilly Lispro is regarded as fast acting insulin, and has a slightly altered protein structure relative to native human insulin. Hoechst regular insulin, maintains the native human insulin protein structure that is chemically similar, but has slower uptake than Lispro when administered by the traditional SC route. Both insulin types were administered in bolus via the ID route to determine if any differences in uptake would be discernable by this route. 5U of either insulin type were administered to the ID space using dermal access microdevice design SS3_34. The insulin concentration verses time data shown in Figure 3. When administered by the ID route the PK profiles for regular and fast-acting insulin were essentially identical, and both insulin types exhibited faster uptake than Lispro given by the traditional SC route. This is evidence that the uptake mechanism for ID administration is less affected by minor biochemical changes in the administered substance, and that ID delivery provides an advantageous PK uptake profile for regular insulin that is superior to SC administered fast-acting insulin.

20

[0068] EXAMPLE IV

[0069] Bolus delivery of Lilly Lispro fast-acting insulin via microneedle arrays having needles of various lengths was conducted to demonstrate that the precise deposition of drug into the dermal space is necessary to obtain the PK advantages and distinctions relative to SC. Thus, 5U of Lilly Lispro fast-acting insulin was administered using dermal access design SS3_34. Additional microdevices of the same needle array configuration were fabricated whereby exposed needle lengths of the microdevice array were lengthened to include arrays with needles lengths of 2 and 3 mm. The average total dermal thickness in Yucatan Mini swine ranges from 1.5-2.5 mm. Therefore insulin deposition is expected to be into the dermis, approximately at the dermal/SC interface, and below the dermis and within the SC for 1mm, 2mm, and 3mm length needles respectively. Bolus insulin administration was as described in EXAMPLE II. Average insulin concentrations verses time are shown in Figure 4. The data clearly shows as microneedle length is increased, the resulting PK profile begins to more closely resemble SC administration. This data demonstrates the benefits of directly targeting the dermal space, such benefits include rapid uptake and distribution, and high initial concentrations. Since the data are averages of multiple examples, they do not show the

35

5 increased inter-individual variability in PK profiles from longer 2 and 3mm
microneedles. This data demonstrates that since skin thickness may vary both between
individuals and even within a single individual, shorter needle lengths that accurately
target the dermal space are more reproducible in their PK profile since they are
depositing the drug more consistently in the same tissue compartment. This data
10 demonstrates longer microneedles that deposit or administer substances deeper into the
dermal space, or partially or wholly into the SC space, mitigate or eliminate the PK
advantages in comparison to shallow, directly targeted administrations to the highly
vascularized dermal region.

15 [0070] EXAMPLE V

[0071] Bolus delivery of Lantus long-acting insulin was delivered via the ID route .
Lantus is an insulin solution that forms microprecipitates at the administration site upon
injection. These microparticulates undergo slow dissolution within the body to provide
(according to the manufacturer's literature) a more stable low level of circulating insulin
20 than other current long-acting insulin such as crystalline zinc precipitates (e.g. Lente,
NPH). Lantus insulin (10 U dose, 100 uL) was administered to diabetic Yucatan Mini
pigs using the dermal access design SS3_34 and by the standard SC method as
previously described. Referring to Figure 5, when administered via the ID route, similar
PK profiles were obtained relative to SC. Minor distinctions include a slightly higher
25 "burst" immediately after the ID insulin delivery. This demonstrates that the uptake of
even very high molecular weight compounds or small particles is achievable via ID
administration. More importantly this supports the fact that the biological clearance
mechanism in the body is not appreciably changed by the administration route, nor is the
way in which that the drug substance is utilized. This is extremely important for drugs
30 compounds that have a long circulating half-life (examples would be large soluble
receptor compounds or other antibodies for cancer treatment, or chemically modified
species such as PEGylated drugs).

[0072] EXAMPLE VI

35 [0073] Bolus ID delivery of human granulocyte colony stimulating factor (GCSF)
(Neupogen) was administered via dermal access microdevice designs SS3_34B (array)
or SS1_34 (single needle) to Yucatan minipigs. Delivery rate was controlled via a

5 Harvard syringe pump and was administered over a 1-2.5 min period. Figure 6 shows the PK availability of GCSF in blood plasma as detected by an ELISA immunoassay specific for GCSF. Administration via IV and SC delivery was performed as controls. Referring to Figure 6 bolus ID delivery of GCSF shows the more rapid uptake associated with ID delivery. C_{max} is achieved at approximately 30-90 minutes vs. 120 min for SC.

10 Also the bioavailability is dramatically increased by an approximate factor of 2 as evidenced by the much higher area under the curve (AUC). Circulating levels of GCSF are detectable for an extended period, indicating that ID delivery does not alter the intrinsic biological clearance mechanism or rate for the drug. These data also show that device design has minimal effect on the rapid uptake of drug from the ID space. The data

15 referred to in Figure 7 also shows the degree and time course of white blood cell expansion as a result of GCSF administration with respect to a negative control (no GCSF administered). White blood cell (WBC) counts were determined by standard cytometric clinical veterinary methods. ID delivery exhibits the same clinically significant biological outcomes. Although all delivery means give approximately equal

20 PD outcomes, this data suggests ID delivery could enable use half the dose to achieve essentially the same physiological result in comparison to SC, due to approximately 2-fold bioavailability increase.

[0074] EXAMPLE VII

25 An ID administration experiment was conducted using a peptide drug entity: human parathyroid hormone 1-34 (PTH). PTH was infused for a 4 h period, followed by a 2 h clearance. Control SC infusion was through a standard 31-gauge needle inserted into the SC space lateral to the skin using a "pinch-up" technique. ID infusion was through dermal access microdevice design SSB1_30 (a stainless steel 30-gauge needle bent at the

30 tip at a 90° angle such that the available length for skin penetration was 1-2 mm). The needle outlet (the tip of the needle) was at a depth of 1.7-2.0 mm in the skin when the needle was inserted. A 0.64 mg/mL PTH solution was infused at a rate of 75 μ L/hr. Flow rate was controlled via a Harvard syringe pump. Weight normalized PTH plasma levels are shown in Figure XX. {The weight normalized delivery profiles show a larger

35 area under the curve (AUC) indicating higher bioavailability, higher peak values at earlier sampling timepoints (e.g. 15 and 30 min) indicating more rapid onset from ID

5 delivery, and rapid decrease following termination of infusion (also indicative of rapid uptake without a depot effect).}

[0075] The above examples and results demonstrate the inventive delivery method using multi-point array ID administration and single needle ID administration results in
10 more rapid uptake with higher C_{max} than SC injection. ID uptake and distribution is ostensibly unaffected by device geometry parameters, using needle lengths of about 0.5 to about 1.7mm, needle number and needle spacing. No concentration limit for biological absorption was found and PK profiles were dictated principally by the concentration-based delivery rate. The primary limitations of ID administration are the
15 total volume and volumetric infusion-rate limits for leak-free instillation of exogenous substances into a dense tissue compartment. Since absorption of drugs from the ID space appears to be insensitive to both device design and volumetric infusion rate, numerous formulation/device combinations can be used to overcome this limitations and provide the required or desired therapeutic profiles. For example, volume limited dosing
20 regimens can be circumvented either by using more concentrated formulations or increasing the total number of instillation sites. In addition, effective PK control is obtained by manipulating infusion or administration rate of substances.

[0076] In general, ID delivery as taught by the methods described hereto via dermal
25 access microneedle devices provides a readily accessible and reproducible parenteral delivery route, with high bioavailability, as well as the ability to modulate plasma profiles by adjusting the device infusion parameters, since uptake is not rate-limited by biological uptake parameters.

[0077] In the previously described examples, the methods practiced by the invention
30 demonstrate the ability to deliver a drug in vivo with greatly improved pharmaceutically relevant rates. This data indicates an improved pharmacological result for ID administration as taught by the methods described of other drugs in humans would be expected according to the methods of the invention.

35

5 [0078] All references cited in this specification are hereby incorporated by reference.
The discussion of the references herein is intended merely to summarize the assertions
made by their authors and no admission is made that any reference constitutes prior art
relevant to patentability. Applicants reserve the right to challenge the accuracy and
10 pertinency of the cited references.

WHAT IS CLAIMED IS:

5 1. A method for directly delivering a substance into an intradermal space within mammalian skin comprising administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm, said outlet being inserted into the skin to a depth of between .3 mm and 2 mm, such that delivery of the substance occurs at a depth between .3 mm and 2 mm.

10

 2. The method according to claim 1 wherein the delivered substance has improved pharmacokinetics compared to pharmacokinetics after subcutaneous injection.

 3. The method of claim 1 wherein the administration is through at least one small
15 gauge hollow needle.

 4. The method of claim 1 wherein the needle has an outlet with an exposed height between 0 and 1 mm.

20 5. The method of Claim 1 wherein injecting comprises inserting the needle to a depth which delivers the substance at least about 0.3 mm below the surface to no more than about 2 mm below the surface.

 6. The method of Claim 1 wherein administering comprises inserting the needle into
25 the skin to a depth of at least about 0.3 mm and no more than about 2 mm.

 7. The method of claim 2 wherein the improved pharmacokinetics is increased bioavailability of the substance.

30 8. The method of claim 2 wherein the improved pharmacokinetics is a decrease in T_{max} .

 9. The method of claim 2 wherein the improved pharmacokinetics is an increase in C_{max} .

35

5 10. The method of claim 2 wherein the improved pharmacokinetics is a decrease in
T_{lag}.

 11. The method of claim 2 wherein the improved pharmacokinetics is enhanced
absorption rate.

10

 12. The method of claim 1 wherein the substance is administered over a time period
of not more than ten minutes.

 13. The method of claim 1 wherein the substance is administered over a time period
15 of greater than ten minutes.

 14. The method of claim 1 wherein the substance is a peptide or protein.

 15. The method of claim 1 wherein the substance is administered at a rate between 1
20 nL/min. and 200 mL/ min.

 16. The method of claim 1 wherein said substance is a hormone.

 17. The method of claim 14 wherein said protein or peptide is selected from the
25 group consisting of insulin, granulocyte stimulating factor and PTH.

 18. The method of claim 1 wherein said substance is a nucleic acid.

 19. The method of claim 1 wherein the substance has a molecular weight of less than
30 1000 daltons.

 20. The method of claim 1 wherein the substance has a molecular weight greater than
1000 daltons.

35 21. The method of claim 1 wherein said substance is hydrophobic.

 22. The method of claim 1 wherein said substance is hydrophilic.

5 23. The method of claim 1 wherein the needle(s) are inserted substantially perpendicularly to the skin.

 24. A method of administering a pharmaceutical substance comprising injecting or infusing the substance intradermally through one or more microneedles having a length and
10 outlet suitable for selectively delivering the substance into the dermis to obtain absorption of the substance in the dermis.

 25. The method of Claim 24 wherein absorption of the substance in the dermis produces improved systemic pharmacokinetics compared to subcutaneous administration.
15

 26. The method of Claim 25 wherein the improved pharmacokinetics is increased bioavailability.

 27. The method of Claim 25 wherein the improved pharmacokinetics is decreased
20 T_{max} .

 28. The method of claim 25 wherein the improved pharmacokinetics is an increase in
 C_{max} .

 29. The method of claim 25 wherein the improved pharmacokinetics is a decrease in
25 T_{lag} .

 30. The method of claim 25 wherein the improved pharmacokinetics is an enhanced absorption rate.
30

 31. The method of claim 24 wherein the length of the microneedle is from about 0.5 mm to about 1.7 mm.

 32. The method of Claim 24 wherein the microneedle is a 30 to 34 gauge needle
35

 33. The method of Claim 24 wherein the microneedle has an outlet of from 0 to 1 mm.

5 34. The method of Claim 24 wherein the microneedle is configured in a delivery device which positions the microneedle perpendicular to skin surface.

 35. The method of Claim 24 wherein the microneedle needle is contained in an array of microneedles needles.

10

 36. The method of Claim 35 wherein the array comprises 3 microneedles.

 37. The method of Claim 35 wherein the array comprises 6 microneedles.

15 38. A microneedle for intradermal injection of a pharmaceutical substance, wherein the microneedle has a length and outlet selected for its suitability for specifically delivering the substance into the dermis.

 39. The microneedle according to claim 38 wherein the length of the microneedle is
20 from about 0.5 mm to about 1.7 mm.

 40. The microneedle of Claim 38 which is a 30 to 34 gauge needle

 41. The microneedle of Claim 38 which has an outlet of from 0 to 1 mm
25

 42. The microneedle of Claim 38 which is configured in a delivery device which positions the microneedle perpendicular to skin surface.

 43. The microneedle of Claim 42 which is in an array of microneedles needles.
30

 44. The microneedle of Claim 43 wherein the array comprises 3 microneedles.

 45. The microneedle of Claim 43 wherein the array comprises 6 microneedles.

5 46. A method for delivering a bioactive substance to a subject comprising :
contacting the skin of the subject with a device having a dermal-access means for accurately
targeting the dermal space of the subject with an efficacious amount of the bioactive
substance.

10 47. The method of claim 46 wherein the pharmacokinetics of the bioactive substance
is improved relative to the pharmacokinetics of the substance when administered
subcutaneously.

 48. The method of claim 47 wherein the improved pharmacokinetics is an increase in
15 bioavailability.

 49. The method of claim 47 wherein the improved pharmacokinetics is a decrease in
 T_{\max} .

20 50. The method of claim 47 wherein the improved pharmacokinetics comprises an
increase in C_{\max} of the substance compared to subcutaneous injection.

 51. The method of claim 47 wherein the improved pharmacokinetics is a decrease in
 T_{lag} .

25 52. The method of claim 47 wherein the improved pharmacokinetics is an enhanced
absorption rate.

 53. The method of Claim 46 wherein the device has a fluid driving means including
a syringe, infusion pump, piezoelectric pump, electromotive pump, electromagnetic pump,
30 or Belleville spring.

 53. The method of Claim 46 wherein the dermal access means comprises one or
more hollow microcannula having a length of from about 0.5 to about 1.7 mm- mm.

35 54. The method of Claim 46 wherein said dermal access means comprises one or
more hollow microcannula having an outlet with an exposed height between 0 and 1 mm.

5 55. A method for delivering a bioactive substance to a subject comprising:
contacting the skin of a subject with a device having a dermal-access means for accurately
targeting the dermal space of the subject with an efficacious amount of the bioactive
substance at a rate of 1 nL/min. to 200 mL/min.

10 56. The method of claim 55 wherein the rapid onset pharmacokinetics of the
bioactive substance is substantially improved relative to subcutaneous injection.

57. The method of claim 56 wherein the bioavailability is increased.

15 58. The method of claim 56 wherein the pharmacokinetics is a decreased T_{max} .

59. The method of claim 56 wherein the pharmacokinetics is an increased C_{max} .

60. The method of claim 56 wherein the pharmacokinetics is a decreased T_{lag} .

20 61. The method of claim 56 wherein the pharmacokinetics is an enhanced absorption
rate.

25 62. The method of Claim 55 wherein the dermal access means has one or more
hollow microcannula that inserts into the skin of said subject to a depth of from about 0.5 to
about-2.0 mm.

63. The method of Claim 55 wherein the dermal access means has one or more
hollow microcannula having an outlet with an exposed height between 0 and 1 mm.






FIG. 1

2/7








FIG. 4




FIG. 5

6/7




FIG. 6




FIG. 7

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/20782

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | US 3 814 097 A (GANDERTON D ET AL) 4 June 1974 (1974-06-04) abstract; claim 1 | 38-45 |
| A | WO 99 64580 A (GEORGIA TECH RES INST) 16 December 1999 (1999-12-16) abstract; claim 7 | 38-45 |
| A | US 5 879 326 A (ANDERSON R ROX ET AL) 9 March 1999 (1999-03-09) abstract | 38-45 |
| A | US 2 619 962 A (ROY ROSENTHAL SOL) 2 December 1952 (1952-12-02) column 2, line 31,32 | 38-45 |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *3* document member of the same patent family

Date of the actual completion of the international search

1 November 2001

Date of mailing of the international search report

12/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Nielsen, M

INTERNATIONAL SEARCH REPORT

Initial Application No

PCT/US 01/20782

| Patent document cited in search report | | Publication date | Patent family member(s) | | Publication date |
|---|---|---------------------|----------------------------|------------|---------------------|
| US 3814097 | A | 04-06-1974 | GB | 1408925 A | 08-10-1975 |
| | | | AR | 195415 A1 | 08-10-1973 |
| | | | AU | 5145073 A | 25-07-1974 |
| | | | BE | 795384 A1 | 13-08-1973 |
| | | | CH | 560544 A5 | 15-04-1975 |
| | | | DE | 2305989 A1 | 23-08-1973 |
| | | | DK | 131270 B | 23-06-1975 |
| | | | FR | 2172168 A1 | 28-09-1973 |
| | | | IT | 995037 B | 10-11-1975 |
| | | | JP | 48093192 A | 03-12-1973 |
| | | | LU | 67007 A1 | 19-04-1973 |
| | | | NL | 7301843 A | 16-08-1973 |
| | | | ZA | 7300459 A | 31-10-1973 |
| WO 9964580 | A | 16-12-1999 | AU | 4561699 A | 30-12-1999 |
| | | | EP | 1086214 A1 | 28-03-2001 |
| | | | WO | 9964580 A1 | 16-12-1999 |
| US 5879326 | A | 09-03-1999 | AU | 5740496 A | 11-12-1996 |
| | | | WO | 9637155 A1 | 28-11-1996 |
| US 2619962 | A | 02-12-1952 | NONE | | |

THIS PAGE BLANK (USPTO)